Display options
Cite
El Rhalete A, Rhazi I, Bensaid A, et al. Benefits of Tocilizumab in patients with a severe form of SARS-CoV-2 infection: Experience of the intensive care unit of the Mohammed VI university hospital, Oujda. Ann Med Surg (Lond). 2021;67:102514doi: 10.1016/j.amsu.2021.102514.
El Rhalete, A., Rhazi, I., Bensaid, A., Diass, S., Kaouini, A., Ounci, E., Abdi, M., Maarad, M., Babouh, C., Alami, Z., Abda, N., Bkiyer, H., & Housni, B. (2021). Benefits of Tocilizumab in patients with a severe form of SARS-CoV-2 infection: Experience of the intensive care unit of the Mohammed VI university hospital, Oujda. Annals of medicine and surgery (2012), 67102514. https://doi.org/10.1016/j.amsu.2021.102514
El Rhalete, Abdelilah, et al. "Benefits of Tocilizumab in patients with a severe form of SARS-CoV-2 infection: Experience of the intensive care unit of the Mohammed VI university hospital, Oujda." Annals of medicine and surgery (2012) vol. 67 (2021): 102514. doi: https://doi.org/10.1016/j.amsu.2021.102514
El Rhalete A, Rhazi I, Bensaid A, Diass S, Kaouini A, Ounci E, Abdi M, Maarad M, Babouh C, Alami Z, Abda N, Bkiyer H, Housni B. Benefits of Tocilizumab in patients with a severe form of SARS-CoV-2 infection: Experience of the intensive care unit of the Mohammed VI university hospital, Oujda. Ann Med Surg (Lond). 2021 Jul;67:102514. doi: 10.1016/j.amsu.2021.102514. Epub 2021 Jun 25. PMID: 34221397; PMCID: PMC8233060.
Copy Download .nbib Format: NLM
Share it on

Ann Med Surg (Lond). 2021 Jul;67:102514. doi: 10.1016/j.amsu.2021.102514. Epub 2021 Jun 25.

Benefits of Tocilizumab in patients with a severe form of SARS-CoV-2 infection: Experience of the intensive care unit of the Mohammed VI university hospital, Oujda.

Annals of medicine and surgery (2012)

Abdelilah El Rhalete, Inas Rhazi, Amine Bensaid, Soufiane Diass, Abderrahim Kaouini, Essaad Ounci, Mohammed Abdi, Mohammed Maarad, Choukri Babouh, Zineb Alami, Naima Abda, Houssam Bkiyer, Brahim Housni

Affiliations

  1. Department of Intensive Care Unit, Mohammed VI University Hospital, Oujda, Morocco.
  2. Faculty of Medicine and Pharmacy, Mohammed 1st University, Oujda, Morocco.
  3. Mohammed First University Oujda, Faculty of Medicine and Pharmacy Oujda, LERCSP, Oujda, Morocco.
  4. Mohammed First University Oujda, FMP Oujda, LAMCESM, Oujda, Morocco.

PMID: 34221397 PMCID: PMC8233060 DOI: 10.1016/j.amsu.2021.102514

Abstract

BACKGROUND: COVID-19 is a new disease that appeared in December 2019. Millions of people have been infected and died from this infection. Until today, the pathophysiology and treatment of this infection remain unknown, but a lot of studies are trying to solve the mystery. The trail of inflammation remains the most convincing, especially the Interleukin 6 (IL-6) which could play an important role in a reaction cascade leading to a cytokine storm. According to studies, although few in number, the Tociluzimab (TCZ), which is an anti-IL6, could prevent or even suppress this storm, leading to a less severe clinical state of the disease and a faster recovery. This could decrease the use of oxygen, avoid the risk of intubation and mortality.

PATIENTS AND METHODS: This single-center retrospective observational case review brought together 557 COVID-19 seriously ill patients (pulmonary involvement> 25% + SatO

RESULTS: The average age of our patients was 62,05 years (±13.51) and 62.61 years (±16.33) respectively in the TCZ versus NON TCZ group. 76 (76%) were men while 24 were women (24%) in the TCZ group; and there was 313 (68.49%) men and 144 (31.51%) women in the NON TCZ group. Their average BMI was 28 kg/m2 (±4.52) in the TCZ group versus 27.89 kg/m2 (±4.73) in the NON TCZ group. Among them, the TCZ group included 38 (38%) diabetic patients, 38 hypertensive (38%), 12 heart disease (12%) and 2 chronic renal failure (2%), while the NON TCZ group regrouped 35 (7.65%) diabetics, 33 (7.22%) hypertensive, 12 heart disease (2.67%), and 5 chronic renal failure (1.09%) patients. The mean time to consultation of patients was almost similar in the two groups: 8.86 (±7,28) days for TCZ and 8.83 (±7,03) days for NON TCZ group. The mean length of ICU hospital stay was 9 days (4,94) for the TCZ group and 8,75 days (4,73) for the other one. The saturation at admission was at 74.92% (10.45) for the TCZ group ranging from 40% to 92%, and at 73,56% for the NON TCZ group. Lung damage from COVID-19 was extensive in 12%, severe in 32%, and critical in 56% of TCZ group enrolled cases. Meanwhile it was extensive in 23.63%, severe in 41,35%, and critical in 35,01% of the NON TCZ group. The biological findings found average of white blood cells at 12256/12082 e/mm

CONCLUSION: The use of Tociluzimab in ICU patients with severe COVID-19 pneumonia did not contribute to a significant difference in the reduction of hospital stay. However, the invasive mechanical ventilation was less needed in patients receiving Tociluzimab than the others. Moreover, there was a mortality benefit associated with the use of Tociluzimab, but only before 10 days of hospitalization.

© 2021 The Authors.

Keywords: COVID-19; Case series; Cytokine storm; Interleukin-6; Morocco; Tocilizumab

Conflict of interest statement

The authors declare no conflicts of interest.

References

  1. J Clin Invest. 2020 May 1;130(5):2620-2629 - PubMed
  2. Cytokine Growth Factor Rev. 2020 Jun;53:13-24 - PubMed
  3. Int J Antimicrob Agents. 2020 May;55(5):105954 - PubMed
  4. Clin Infect Dis. 2020 Nov 5;71(8):1937-1942 - PubMed
  5. Int J Infect Dis. 2020 Oct;99:338-343 - PubMed
  6. Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975 - PubMed
  7. Am J Clin Pathol. 2016 May;145(5):646-50 - PubMed
  8. Int J Surg. 2020 Dec;84:231-235 - PubMed
  9. Bioorg Med Chem. 2020 Mar 1;28(5):115327 - PubMed
  10. Best Pract Res Clin Rheumatol. 2012 Feb;26(1):157-65 - PubMed
  11. Lancet. 2020 Feb 15;395(10223):507-513 - PubMed
  12. Rev Med Virol. 2020 Nov;30(6):1-9 - PubMed

Publication Types